

<b>Reference:</b>	FOI.16712.25
<b>Subject:</b>	Transgender healthcare
<b>Date of Request:</b>	2 March 2025

**Requested:**

I use the word 'trans' here to encompass all people who identify with a gender other than that assigned at birth or who may be questioning their gender.

My questions (except 6 and 7) relate to the period from April 2024–present.

1. Has advice been issued to local GP surgeries about registering and/or treating trans-identifying patients? If so, please provide the relevant documents.
2. Has the local formulary been edited in relation to the prescription of any of the following. Please describe any changes in relation to which providers are allowed to prescribe it to which patient populations, including age, assigned sex, and gender identity. (E.g. Previously GPs were allowed to initiate prescriptions of [medication] to [gender identity/ assigned sex] beginning at [age] but now the prescription must be initiated by a specialist, and cannot begin before [age])
  - a. testosterone (all formulations)
  - b. estrogen (all formulations)
  - c. GnRH agonists
  - d. progesterone (all formulations)
  - e. Spironolactone
  - f. Bicalutamide
  - g. Cyproterone
3. Have any new local services for trans adults been commissioned? If so, please provide details of the treatments offered and specify the age group served.
4. Have any new local services for trans children been commissioned? If so, please provide details of the treatments offered and specify the age group served.
5. Have any local services for trans children or trans adults been discontinued?
6. How many complaints have you received about access to transition-related care. Please provide data for the past three years.
7. How many complaints have you received about trans people's access to non-transition-related care? Please provide data for the past three years.

**Response:**

1. Hywel Dda University Health Board (UHB) confirms that no advice documents have been issued to local GP surgeries about registering and/or treating trans-identifying patients during the period 1 April 2024 to 18 March 2025. However, the UHB has a Local Supplementary Service for the management of patients, and accompanying advice is available on the UHB's webpage for GP practices to download and utilise.

The UHB is applying an exemption under Section 21 of the Freedom of Information Act 2000 (FoIA) to the requested information, as it is already in the public domain, and is accessible by another means. The UHB has previously answered a similar Freedom of Information request, which is available on our disclosure log:

- FOI.14384 – Local Enhanced Services (LES) – Attachment 11
- FOI.14384 – Local Enhanced Services (LES) – Attachment 18

Additionally, the UHB adheres to the All Wales Medicines Strategy Group document titled 'Endocrine Management of Gender Dysphoria in Adults - Prescribing Guidance for Non-specialist Practitioners' which can be found using the below link:

[Endocrine-management-of-gender-dysphoria-in-adults.pdf](#)

2. The UHB adheres to the All Wales Medicines Strategy Group Guideline titled 'Endocrine Management of Gender Incongruence in Adults'. Details of this guidance can be found using this link:

<https://awttc.nhs.wales/files/guidelines-and-pils/endocrine-management-of-gender-incongruence-in-adults-pdf/>

The guidance outlines the prescribing responsibilities of the Welsh Gender Team, the Local Gender Team and General Medical Practitioners. There have been two (2) minor updates to this guidance since April 2024 that have not been added to the formulary, as the Pharmacy Team directs prescribers to the original document to allow them to have the full context.

3. – 4. The UHB confirms that there have been no new local services for transgender children or adults commissioned.
5. The UHB confirms that no local services for transgender children or adults have been discontinued.
6. The UHB confirms that it has not received any complaints about the access to transition-related care during the last three years.
7. The UHB confirms that it has not received any complaints about transgender access to non-transition-related care during the last three years.